DNA RNA and Cells

03 Jan 2017 Kite Pharma Submits Investigational New Drug (IND) Application for KITE-718, an Investigational Next Generation T-Cell Receptor (TCR) Therapy Targeting Cancer Antigens MAGE A3 and MAGE A6
29 Dec 2016 CardiAMP Pivotal Heart Failure Trial Initiated at Two US Centers
29 Dec 2016 City of Hope Researchers Achieve Remission Using CAR-T Cell Therapy for Aggressive Brain Tumors
24 Dec 2016 SPINRAZA™ (nusinersen) Approved in U.S. to Treat Broad Range of Patients with Spinal Muscular Atrophy
21 Dec 2016 Lion Biotechnologies Announces New Sponsored Research and Clinical Grant Agreements with H. Lee Moffitt Cancer Center and Research Institute
21 Dec 2016 MaxCyte Announces Strategic Immuno-Oncology Collaboration to Advance New Generation of CAR-based Cell Therapies
21 Dec 2016 GenSight Biologics Reports Sustained Visual Acuity Gain at 78 Weeks in Its Phase I/II Study with GS010 for the Treatment of Leber’s Hereditary Optic Neuropathy (LHON)
21 Dec 2016 Juno Therapeutics’ and Celgene Corporation’s Investigational Drug JCAR017 Granted Breakthrough Therapy Designation from FDA and Priority Medicines Eligibility from EMA for Relapsed/Refractory Diffuse Large B-cell Lymphoma
21 Dec 2016 Ionis and AstraZeneca Advance First Generation 2.5 LICA Drug into Preclinical Development to Treat Cardiovascular Disease
19 Dec 2016 Akcea and Ionis Announce Positive Results from Compass Phase 3 Study of Volanesorsen
19 Dec 2016 Adaptimmune and Bellicum Pharmaceuticals Enter a Strategic Collaboration to Evaluate Next-Generation T-Cell Therapies
17 Dec 2016 Ionis Earns $28 Million from AstraZeneca for a New Drug to Treat Cancer
17 Dec 2016 AOBiome Launches Phase 2 Clinical Trial Using Novel Bacterial Platform for Treatment of Hypertension
16 Dec 2016 Cellectis Announces Recombinant DNA Advisory Committee’s (RAC) Unanimous Approval of UCART123 Phase 1 Study Protocols in AML and BPDCN
16 Dec 2016 bluebird bio and apceth Biopharma Establish Commercial Drug Product Manufacturing Agreement
15 Dec 2016 Kiadis Pharma announces initiation of a Phase I/II clinical trial with ATIR201™ for thalassemia
14 Dec 2016 bluebird bio Announces First Patient Treated with LentiGlobinTM Drug Product in Northstar-2 (HGB-207) Phase 3 Trial of Patients with Transfusion-Dependent β-Thalassemia
14 Dec 2016 TILT Biotherapeutics Secures 10 M€ ($10.6M) for Viral Cancer T-Cell Immunotherapy
14 Dec 2016 FDA approves first autologous cellularized scaffold for the repair of cartilage defects of the knee
13 Dec 2016 Dimension Therapeutics Announces FDA Acceptance of Investigational New Drug Application for DTX301 to Treat OTC Deficiency
12 Dec 2016 Kite Pharma Announces Publication of T-Cell Therapy Targeting Mutant KRAS in Cancer by the National Cancer Institute (NCI) in New England Journal of Medicine
12 Dec 2016 NantKwest Announces Enhanced High-Affinity Activated Natural Killer (haNK) Cell Therapy in Preclinical Studies of HER2 Positive Breast Cancer at Presentation at the San Antonio Breast Cancer Symposium
12 Dec 2016 Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD)
07 Dec 2016 Juno Therapeutics Highlights Progress with Best-in-Class Strategy in B-Cell Malignancies at ASH
06 Dec 2016 Kite Pharma Presents Results of Multi-Center Pivotal ZUMA-1 Trial of Axicabtagene Ciloleucel (KTE-C19) in Aggressive Non-Hodgkin Lymphoma as Late-Breaking Abstract at Annual Meeting of American Society of Hematology

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing